Hainan Huluwa Pharmaceutical Group Co., Ltd.
SHH: 605199.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jinping Liu
- Employees
- 2,103
- Headquarters
- Haikou, China
- IPO year
- 2020
- Market cap
- CN¥2.7B
- Website
- https://www.huluwayaoye.com
Loading 605199…
Loading profile data…Frequently asked questions about 605199
What does Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS) do?
Hainan Huluwa Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of drugs in the areas of Children's respiratory and digestive systems in China. Its primary products include 4 grams of pediatric lung heat cough granules and capsules. The company was founded in 2005 and is based in Haikou, China.
Where does 605199.SS trade?
Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS) trades on the Shanghai Stock Exchange.
What sector is 605199.SS in?
Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Hainan Huluwa Pharmaceutical Group Co., Ltd.?
Jinping Liu is the chief executive officer of Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS).
Where is Hainan Huluwa Pharmaceutical Group Co., Ltd. headquartered?
Hainan Huluwa Pharmaceutical Group Co., Ltd. is headquartered in China.
Does 605199.SS pay a dividend?
Yes — Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS) paid a trailing twelve-month dividend of CNY 0.13 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 605199.SS go public?
Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS) completed its initial public offering in 2020.